Abstracts tagged "methotrexate (MTX)"

Abstract Number: 3239 • 2015 ACR/ARHP Annual Meeting
Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years
Carolin Krause¹, Siegfried Wassenberg², Rolf Rau³, Gertraud Herborn⁴, Juergen Braun⁵ and Dietmar Krause⁶, ¹University Munster, Munster, Germany, ²Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, ³Expert in Rheumatology, Düsseldorf, Germany, ⁴Evangelisches Fachkrankenhaus Ratingen, Ratingen, Greece, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany
Background/Purpose: Methotrexate (MTX) is considered as the anchor drug for the treatment of patients with rheumatoid arthritis (RA). MTX has been shown to reduce disease…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3247 • 2015 ACR/ARHP Annual Meeting
Dietary Intake of Omega-3 Fatty Acids and Vitamin C and D Associate with Decreased Pain, Independent of Inflammation, in MTX Treated Early RA Patients
Cecilia Lourdudoss¹, Alicja Wolk², Lars Alfredsson³, Lars Klareskog⁴, Ronald F. van Vollenhoven⁵ and Jon Lampa⁶, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, ³The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁶Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Chronic pain is common in RA and considered as the major disease burden from the patients’ perspective. Earlier data suggest that omega-3 fatty acids,…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 2474 • 2014 ACR/ARHP Annual Meeting
Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
Jessica Gunn, Aikaterina Panopolou and Alan Steuer, Rheumatology, Wexham Park Hospital, Slough, United Kingdom
Background/Purpose: Methotrexate (MTX) monotherapy or MTX in combination with other conventional and biologic disease-modifying antirheumatic drugs (DMARDs) is standard treatment for patients with inflammatory arthritis.…
Abstract Number: 457 • 2014 ACR/ARHP Annual Meeting
First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Kazuhiko Yamamoto¹, Hajime Goto², Kenzo Hirao³, Atsuo Nakajima⁴, Hideki Origasa⁵, Nobuhiro Takagi⁶, Minako Tomobe⁷ and Kyoichi Totsuka⁸, ¹Allergy & Rheumatology, Univ Tokyo Gr School of Med, Tokyo, Japan, ²Fukujuji Hospital, Tokyo, Japan, ³Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan, ⁵Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁶Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ⁷Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ⁸Kitatama Hospital, Tokyo, Japan
Background/Purpose: To evaluate the long-term safety of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Japan. Methods: In…
Abstract Number: 2467 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics NaÃ¯ve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-NaÃ¯ve RA Patients Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Kunihiko Tanaka¹⁰ and Hisashi Yamanaka¹¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Medicine II School of Medicine, Hokkaido University, Sapporo, Japan, ³Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka, Japan, ⁶Dept Internal Medicine, Univ of Tsukuba/Inst Clin Med, Tsukuba City, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁸First Dept of Internal Med, U Occupa & Environ Hlth, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient PMS study of tocilizumab (TCZ) followed 7901 RA patients for 28 wks. That study (hereafter, PMS7901) showed patients with a high probability…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 2438 • 2014 ACR/ARHP Annual Meeting
A Multi-Centre Survey of Tolerability Problems for Patients on Regular Methotrexate
David Walker¹, Emmanuel George², Sarah Gibson³, Una Martin⁴, Hilary Wrightson⁵, Peta S. Heslop⁶, Peter Prowse⁷, Matthew Kalinowski⁷, Adewale O. Adebajo⁸, David Marshall⁹, Michael Reed¹⁰ and Sandra M. Robinson⁶, ¹Dept of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ²Rheumatology, Wirral University Teaching Hospital NHS Foundation Trust, The Wirral, United Kingdom, ³Rheumatology, WIRRAL UNIVERSITY TEACHING HOSPITAL NHS FOUNDATION TRUST, The Wirral, United Kingdom, ⁴Rheumatology, Waterford Regional Hospital, Waterford, United Kingdom, ⁵Rheumatology, Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ⁶R&D, North Tyneside General Hospital, North Shields, United Kingdom, ⁷Rheumatology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom, ⁸Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁹Department of Rheumatology, Inverclyde Royal Hospital, Greenock, United Kingdom, ¹⁰Rheumatology, Inverclyde Royal Hospital, Greenock, United Kingdom
Background/Purpose Methotrexate has become the core DMARD for the treatment of Rheumatoid Arthritis. It has also found utility in treating other forms of inflammatory arthritis…
Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 2393 • 2014 ACR/ARHP Annual Meeting
Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
Gurjit S. Kaeley¹, Midori Jane Nishio², Daryl MacCarter³, Jenny Griffith⁴, Hartmut Kupper⁵, Vishvas Garg⁶ and Jasmina Kalabic⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose Methotrexate (MTX) is used in monotherapy or in combination with other DMARDs in the treatment of patients (pts) with rheumatoid arthritis (RA). We evaluated…
Abstract Number: 187 • 2014 ACR/ARHP Annual Meeting
Revision Arthroplasty in Rheumatoid and Osteoarthritis: Does Methotrexate Decrease Radiographic Lucency in RA Patients?
Mike Wei¹, Douglas N. Mintz², Lisa A. Mandl³, Arielle Fein⁴, Jayme C. Burket⁵, Yuo-Yu Lee⁴, Wei-Ti Huang⁶, Vivian P. Bykerk⁴, Mark P. Figgie⁷, Edward F. DiCarlo⁸, Bruce N. Cronstein⁹ and Susan M. Goodman³, ¹Weill Cornell Medical College, New York, NY, ²Radiology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ⁶Biostatistics, Hospital for Special Surgery, New York, NY, ⁷Orthopedics, Hospital for Special Surgery, New York, NY, ⁸Pathology, Hospital for Special Surgery, New York, NY, ⁹NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Rheumatoid arthritis (RA) patients have excellent total hip arthroplasty (THA) survival, and methotrexate (MTX), an anti-inflammatory disease modifying drug which may affect bone reabsorption,…
Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Miguel Perez-Aso¹, M. Carmen Montesinos², Aranzazu Mediero³, Peter H. Schafer⁴ and Bruce N. Cronstein⁵, ¹545 1st Ave., New York University, New York City, NY, ²Departament de Farmacologia, Facultat de Farmàcia,, Universitat de València, Valencia, Spain, ³Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ⁴Celgene Corporation, Celgene Corporation, Summit, NJ, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…
Abstract Number: 122 • 2014 ACR/ARHP Annual Meeting
The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission
Gurjit S. Kaeley¹, Midori Jane Nishio², Janak Goyal³, Daryl MacCarter⁴, Alvin Wells⁵, Anabela Cardoso⁶, Shufang Liu⁷, Jasmina Kalabic⁸ and Hartmut Kupper⁸, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Raritan Bay Medical Center, Perth Amboy, NJ, ⁴Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁵Rheumatology & Immunotherapy Center, Franklin, WI, ⁶AbbVie, Amadora, Portugal, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose Patients (pts) with rheumatoid arthritis (RA), who achieve clinical disease remission by treatment with disease- modifying agents may have residual joint inflammation and vascularization,…

« Previous Page
1
…
8
9
10
11
12
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].